ClinicalTrials.gg
CompletedNCT01648582AWARD-CHN2Updated Sep 18, 2019Results posted

A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

A Phase 3 interventional study of Dulaglutide and Insulin glargine in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 30 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
774
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
8th of 54
774 · median 159
Started
2012
with 7 others
Phase 3
22 of 54
1 open now
Registered
25th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 25th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (OAM) (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended by their healthcare providers.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes mellitus for at least 6 months
  • Have been taking metformin and/or a sulfonylurea for at least 3 months before screening and have been on a stable therapeutic dose for at least 8 weeks
  • Glycosylated () value of ≥7.0% to ≤11.0%
  • Adult men or adult non-pregnant, non-breastfeeding women
  • (BMI) of ≥19.0 to ≤35.0 kilograms/square meter (kg/m\^2)
  • Stable weight (±5%) ≥3 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus
  • Have previous treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 analog, or any other incretin mimetic
  • Have treatment with dipeptidyl peptidase-IV (DPP-IV) inhibitor, an alpha-glucosidase inhibitor (AGI), thiazolidinedione (TZD), or glinide
  • Have gastric emptying abnormality
  • Have cardiac disorder defined as unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, arrhythmia, , or stroke
  • Have poorly controlled hypertension (systolic blood pressure above 160 millimeter of mercury[mmHg] or diastolic blood pressure above 95 mmHg)
  • Have impaired liver function
  • Have impaired kidney function
  • Have history of chronic pancreatitis or acute pancreatitis
  • Have a serum calcitonin ≥20 picograms per milliliter (pg/mL)
  • Have a personal or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma, or multiple endocrine neoplasia type 2 (MEN 2)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
774 participants (actual)

Study arms

  • Experimental
    1.5 mg Dulaglutide

    1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.

    Drug: Dulaglutide · Drug: Metformin · Drug: Sulfonylureas

  • Experimental
    0.75 mg Dulaglutide

    0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.

    Drug: Dulaglutide · Drug: Metformin · Drug: Sulfonylureas

  • Active comparator
    Insulin Glargine

    Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.

    Drug: Insulin glargine · Drug: Metformin · Drug: Sulfonylureas

Interventions

  • Administered SC

    Also known as: LY2189265

  • Administered SC per dosing titration schedule

  • Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.

  • DrugSulfonylureas

    Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.

    Time frame: Baseline, 26 Weeks

Secondary outcomes

  1. Change From Baseline in HbA1c at 52 Weeks

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means of change from baseline in HbA1c were calculated using a MMRM with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was as the random effect.

    Time frame: Baseline, 52 Weeks

  2. Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks and 52 Weeks

    The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.

    Time frame: Up to 26 and 52 weeks

  3. Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks

    LS means of change from baseline were calculated using MMRM with the change in FBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.

    Time frame: Baseline, 26 Weeks, 52 Weeks

  4. Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks

    Participants were required to perform 7-point SMBG profiles on 2 separate, nonconsecutive days during the 2 weeks before randomization and Weeks 8, 14, 20, 26, 39, and 52 (or the Early Discontinuation Visit). SMBG measurements were taken using a plasma-equivalent blood glucose (BG) meter at 7 time points: morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. Mean and Week 26 and Week 52 was assessed in all treatment groups. LS means of change from baseline were calculated using MMRM with the change in 7-point SMBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.

    Time frame: Baseline, 26 Weeks, 52 Weeks

  5. Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks

    The updated Homeostasis Model Assessment (HOMA2) was used to quantify steady state beta-cell function (%B). HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate %B as a percentage of a normal reference population. LS means were calculated using a homeostasis model assessment with change from baseline in HOMA-%B as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.

    Time frame: Baseline, 26 weeks, 52 weeks

  6. Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks

    The HOMA2 was used to estimate the steady-state insulin sensitivity (%S). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of the normal reference population. LS means were calculated using an homeostasis model assessment with change from baseline in HOMA-%S as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.

    Time frame: Baseline, 26 Weeks, 52 Weeks

  7. Rate of Hypoglycemic Events

    Hypoglycemic events (HE) were classified as documented symptomatic hypoglycemia, asymptomatic hypoglycemia, severe hypoglycemia, and probable symptomatic hypoglycemia. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks and 52 weeks

  8. Number of Self-reported Hypoglycemic Events

    Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia, and had a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 Weeks and 52 Weeks

  9. Change From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)

    Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 Weeks, 52 Weeks

  10. Change From Baseline at 26 Weeks and 52 Weeks on Pulse Rate

    Seated pulse rate was measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

    Time frame: Baseline, 26 Weeks, 52 Weeks

  11. Change From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex.

    Time frame: Baseline, 26 Weeks, 52 Weeks

  12. Change From Baseline in Electrocardiogram Parameters, Heart Rate (HR)

    Time frame: Baseline, 26 Weeks, 52 Weeks

  13. Change From Baseline in Pancreatic Enzymes

    Amylase (total and pancreas-derived) and lipase concentrations were measured

    Time frame: Baseline, 26 Weeks, 52 Weeks

  14. Change From Baseline in Serum Calcitonin

    Time frame: Baseline, 26 Weeks, 52 Weeks

  15. Number of Participants With Adjudicated Cardiovascular (CV) Events

    Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 weeks

  16. Number of Participants With Adjudicated Pancreatitis

    The number of participants with pancreatitis confirmed by adjudication is summarized. Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 52 Weeks

  17. Change From Baseline in Body Weight

    Time frame: Baseline, 26 Weeks, 52 Weeks

  18. Change in Body Mass Index

    Body mass index is an estimate of body fat based on body weight divided by height squared.

    Time frame: Baseline, 26 Weeks, 52 Weeks

  19. Percentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)

    Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant was considered to have TE dulaglutide ADA if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

    Time frame: Baseline through 52 Weeks

  20. EQ-5D Health State Score Responses

    The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life. It consists of 2 parts. The first part assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 3 response categories is summarized for each of the 5 dimensions.

    Time frame: Baseline, 26 Weeks, 52 Weeks

  21. Change From Baseline in EQ-5D Visual Analog Scale Score

    The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. LS means of change from baseline were calculated using ANCOVA and adjusted by treatment, country, and baseline.

    Time frame: Baseline, 26 weeks, 52 weeks

07

Results

Posted Jul 24, 2015

Participant flow

Participant flow — Overall Study
Milestone1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Started258257259
Received at least one dose of study drug258257259
Modified intent-to-treat population253252250
Completed226219227
Not completed323832
Withdrew: Adverse event6112
Withdrew: Lost to follow-up968
Withdrew: Protocol violation121
Withdrew: Withdrawal by subject151717
Withdrew: Physician decision013
Withdrew: Death100
Withdrew: Sponsor decision011

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
percentage of HbA1c1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks-1.73 ± 0.067-1.33 ± 0.067-1.16 ± 0.067
Statistical analysis
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mean difference (net): -0.57 · 95% CI -0.74 to -0.40
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mean difference (net): -0.18 · 95% CI -0.35 to -0.01
SecondaryChange From Baseline in HbA1c at 52 Weeks

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means of change from baseline in HbA1c were calculated using a MMRM with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was as the random effect.

Time frame:
Baseline, 52 Weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c at 52 Weeks
percentage of HbA1c1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Change From Baseline in HbA1c at 52 Weeks-1.47 ± 0.076-1.03 ± 0.076-0.89 ± 0.075
Statistical analysis
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mean difference (net): -0.57 · 95% CI -0.77 to -0.38
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mean difference (net): -0.13 · 95% CI -0.33 to -0.06
SecondaryPercentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks and 52 Weeks

The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.

Time frame:
Up to 26 and 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks and 52 Weeks
percentage of participants1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
HbA1c <7%, Week 2664.852.840.0
HbA1c ≤6.5%, Week 2651.438.921.6
HbA1c <7%, Week 5251.845.632.0
HbA1c ≤6.5%, Week 5237.231.317.2
Statistical analysis
  • 1.5 mg Dulaglutide vs Insulin Glargine · Fisher Exact · p = <0.001
  • 0.75 mg Dulaglutide vs Insulin Glargine · Fisher Exact · p = 0.004
  • 1.5 mg Dulaglutide vs Insulin Glargine · Fisher Exact · p = <0.001
  • 0.75 mg Dulaglutide vs Insulin Glargine · Fisher Exact · p = <0.001
  • 1.5 mg Dulaglutide vs Insulin Glargine · Fisher Exact · p = <0.001
  • 0.75 mg Dulaglutide vs Insulin Glargine · Fisher Exact · p = 0.002
  • 1.5 mg Dulaglutide vs Insulin Glargine · Fisher Exact · p = <0.001
  • 0.75 mg Dulaglutide vs Insulin Glargine · Fisher Exact · p = <0.001
SecondaryChange From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks

LS means of change from baseline were calculated using MMRM with the change in FBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.

Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks
millimoles per liter (mmol/L)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Change from baseline in FBG, 26 Weeks-2.35 ± 0.162-1.71 ± 0.161-2.59 ± 0.161
Change from baseline in FBG, 52 Weeks-2.23 ± 0.166-1.53 ± 0.165-2.35 ± 0.164
Statistical analysis
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.177 · Mean difference (net): 0.24 · 95% CI -0.11 to 0.59
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): 0.88 · 95% CI 0.53 to 1.23
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.518 · Mean difference (net): 0.12 · 95% CI -0.25 to 0.50
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): 0.82 · 95% CI 0.45 to 1.20
SecondaryChange From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks

Participants were required to perform 7-point SMBG profiles on 2 separate, nonconsecutive days during the 2 weeks before randomization and Weeks 8, 14, 20, 26, 39, and 52 (or the Early Discontinuation Visit). SMBG measurements were taken using a plasma-equivalent blood glucose (BG) meter at 7 time points: morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. Mean and Week 26 and Week 52 was assessed in all treatment groups. LS means of change from baseline were calculated using MMRM with the change in 7-point SMBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.

Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Least squares mean · mmol/L
Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks
mmol/L1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Morning pre-meal, Week 26-2.18 ± 0.104-1.89 ± 0.103-2.83 ± 0.103
Morning 2 hours post-meal, Week 26-3.81 ± 0.190-3.43 ± 0.188-3.32 ± 0.188
Mid-day pre-meal, Week 26-2.45 ± 0.159-2.07 ± 0.157-2.10 ± 0.157
Mid-day 2 hours post-meal, Week 26-3.16 ± 0.182-2.71 ± 0.179-2.11 ± 0.179
Evening pre-meal, Week 26-2.25 ± 0.150-1.74 ± 0.147-1.62 ± 0.148
Evening 2 hours post-meal, Week 26-3.00 ± 0.180-2.58 ± 0.178-2.11 ± 0.178
Bed time, Week 26-2.95 ± 0.170-2.51 ± 0.167-2.16 ± 0.167
Morning pre-meal, Week 52-2.06 ± 0.108-1.76 ± 0.108-2.83 ± 0.107
Morning 2 hours post-meal, Week 52-3.58 ± 0.201-3.25 ± 0.200-3.05 ± 0.197
Mid-day pre-meal, Week 52-2.37 ± 0.162-1.89 ± 0.162-1.94 ± 0.160
Mid-day 2 hours post-meal, Week 52-2.75 ± 0.187-2.61 ± 0.186-2.12 ± 0.184
Evening pre-meal, Week 52-2.15 ± 0.159-1.61 ± 0.158-1.51 ± 0.156
Evening 2 hours post-meal, Week 52-2.93 ± 0.183-2.54 ± 0.182-2.10 ± 0.180
Bed time, Week 52-2.90 ± 0.172-2.50 ± 0.171-1.91 ± 0.168
Statistical analysis
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): 0.65 · 95% CI 0.42 to 0.88
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): 0.94 · 95% CI 0.71 to 1.17
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.024 · Mean difference (net): -0.49 · 95% CI -0.92 to -0.07
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.617 · Mean difference (net): -0.11 · 95% CI -0.53 to 0.32
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.055 · Mean difference (net): -0.35 · 95% CI -0.70 to 0.01
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.855 · Mean difference (net): 0.03 · 95% CI -0.32 to 0.39
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): -1.05 · 95% CI -1.46 to -0.64
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.004 · Mean difference (net): -0.60 · 95% CI -1.01 to -0.19
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.63 · 95% CI -0.97 to -0.29
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.489 · Mean difference (net): -0.12 · 95% CI -0.45 to 0.22
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.89 · 95% CI -1.30 to -0.48
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.024 · Mean difference (net): -0.47 · 95% CI -0.88 to -0.06
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.79 · 95% CI -1.17 to -0.41
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.067 · Mean difference (net): -0.35 · 95% CI -0.73 to -0.03
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): 0.77 · 95% CI 0.52 to 1.01
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): 1.06 · 95% CI 0.82 to 1.31
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.025 · Mean difference (net): -0.53 · 95% CI -1.00 to -0.07
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.384 · Mean difference (net): -0.21 · 95% CI -0.67 to 0.26
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.024 · Mean difference (net): -0.43 · 95% CI -0.80 to -0.06
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.783 · Mean difference (net): -0.05 · 95% CI -0.32 to 0.42
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.004 · Mean difference (net): -0.63 · 95% CI -1.07 to -0.20
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.029 · Mean difference (net): -0.48 · 95% CI -0.92 to -0.05
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.64 · 95% CI -1.01 to -0.27
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.603 · Mean difference (net): -0.10 · 95% CI -0.47 to 0.27
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.83 · 95% CI -1.26 to -0.41
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.039 · Mean difference (net): -0.45 · 95% CI -0.87 to -0.02
  • 1.5 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.99 · 95% CI -1.39 to -0.60
  • 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.003 · Mean difference (net): -0.59 · 95% CI -0.98 to -0.20
SecondaryChange From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks

The updated Homeostasis Model Assessment (HOMA2) was used to quantify steady state beta-cell function (%B). HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate %B as a percentage of a normal reference population. LS means were calculated using a homeostasis model assessment with change from baseline in HOMA-%B as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Least squares mean · percentage of HOMA2-%B
Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks
percentage of HOMA2-%B1.5 mg Dulaglutide0.75 mg Dulaglutide
Insulin-Based HOMA2-%B, 26 Weeks34.41 ± 3.83131.17 ± 3.761
Insulin-Based HOMA2-%B, 52 Weeks45.12 ± 4.14736.64 ± 4.061
Statistical analysis
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.352 · Mean difference (net): 34.41
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.352 · Mean difference (net): 31.17
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.025 · Mean difference (net): 45.12
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.025 · Mean difference (net): 36.64
SecondaryChange From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks

The HOMA2 was used to estimate the steady-state insulin sensitivity (%S). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of the normal reference population. LS means were calculated using an homeostasis model assessment with change from baseline in HOMA-%S as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.

Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Least squares mean · percentage of HOMA2-%S
Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks
percentage of HOMA2-%S1.5 mg Dulaglutide0.75 mg Dulaglutide
Insulin-Based HOMA2-%S, Week 26-6.86 ± 3.649-10.03 ± 3.591
Insulin-Based HOMA2-%S, Week 52-10.19 ± 3.677-12.32 ± 3.609
Statistical analysis
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.025 · Mean difference (net): 36.57
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.025 · Mean difference (net): 30.42
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.029 · Mean difference (net): 41.02
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = 0.029 · Mean difference (net): 35.19
SecondaryRate of Hypoglycemic Events

Hypoglycemic events (HE) were classified as documented symptomatic hypoglycemia, asymptomatic hypoglycemia, severe hypoglycemia, and probable symptomatic hypoglycemia. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks and 52 weeks
Reported as:
Mean · events per participant per year
Rate of Hypoglycemic Events
events per participant per year1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
1-year Rate of HE, Week 261.27 ± 4.4850.98 ± 4.2022.13 ± 6.724
Severe HE Week 26NA ± NANA ± NANA ± NA
Nocturnal HE Week 260.19 ± 0.9040.13 ± 0.7620.38 ± 1.444
1-year Rate of HE, Week 520.89 ± 3.7770.80 ± 3.9141.92 ± 6.983
Severe HE Week 52NA ± NANA ± NANA ± NA
Nocturnal HE Week 520.11 ± 0.4880.10 ± 0.5510.31 ± 1.261
SecondaryNumber of Self-reported Hypoglycemic Events

Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia, and had a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 Weeks and 52 Weeks
Reported as:
Number · percentage of participants
Number of Self-reported Hypoglycemic Events
percentage of participants1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Total HE Week 2619.416.729.6
Severe HE Week 260.00.00.0
Nocturnal HE Week 266.23.911.1
Documented Symptomatic Week 2611.27.817.0
Asymptomatic HE Week 2610.18.214.2
Probable HE Week 264.35.17.5
Total HE Week 5222.519.834.8
Severe HE Week 520.00.00.0
Nocturnal HE Week 527.04.313.8
Documented Symptomatic HE Week 5212.49.720.6
Asymptomatic HE Week 5212.010.119.4
Probable HE Week 524.75.48.3
SecondaryChange From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)

Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)]
Change From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)
millimeters of mercury (mmHg)]1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
SBP 26 Weeks-5.53 ± 12.037-2.77 ± 11.920-2.22 ± 12.743
DBP 26 Weeks-1.58 ± 7.842-0.92 ± 7.898-1.61 ± 8.417
SBP 52 Weeks-2.18 ± 11.134-0.61 ± 12.081-0.25 ± 11.717
DBP 52 Weeks-0.19 ± 7.5420.44 ± 7.582-1.13 ± 8.810
Statistical analysis
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.008 (Overall p-value)
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.584 (Overall p-value)
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.169 (Overall p-value)
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = 0.110 (Overall p-value)
SecondaryChange From Baseline at 26 Weeks and 52 Weeks on Pulse Rate

Seated pulse rate was measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.

Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline at 26 Weeks and 52 Weeks on Pulse Rate
beats per minute (bpm)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Change From Baseline on Pulse rate at Week 264.63 ± 8.6810.65 ± 8.631-0.86 ± 9.546
Change From Baseline on Pulse rate at Week 524.18 ± 8.3363.18 ± 8.9170.07 ± 8.205
Statistical analysis
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Overall p-value)
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Overall p-value)
SecondaryChange From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex.

Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Mean · millisecond (msec)
Change From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
millisecond (msec)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
QTcF Interval 26 Weeks-1.65 ± 13.1570.76 ± 11.6432.56 ± 11.911
PR Interval 26 Weeks3.09 ± 1.7002.88 ± 10.801-0.86 ± 10.272
QTcF Interval 52 Weeks0.55 ± 11.2091.19 ± 12.1654.03 ± 11.446
PR Interval 52 Weeks3.60 ± 12.4253.55 ± 11.5260.63 ± 11.861
SecondaryChange From Baseline in Electrocardiogram Parameters, Heart Rate (HR)
Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Electrocardiogram Parameters, Heart Rate (HR)
beats per minute (bpm)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Week 266.13 ± 8.9243.77 ± 9.002-0.46 ± 9.329
Week 525.04 ± 8.2233.40 ± 7.9860.43 ± 8.060
SecondaryChange From Baseline in Pancreatic Enzymes

Amylase (total and pancreas-derived) and lipase concentrations were measured

Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Mean · Units/Liter (U/L)
Change From Baseline in Pancreatic Enzymes
Units/Liter (U/L)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Amylase, Total 26 Weeks7.50 ± 18.7557.54 ± 22.388-0.37 ± 18.196
Amylase, pancreas derived 26 Weeks5.83 ± 14.6075.14 ± 19.360-0.21 ± 11.287
Lipase 26 Weeks11.00 ± 34.13410.67 ± 39.989-2.74 ± 21.818
Amylase, Total 52 Weeks7.82 ± 16.2506.42 ± 20.6750.64 ± 18.696
Amylase, pancreas derived 52 Weeks5.48 ± 12.4494.05 ± 15.490-0.49 ± 12.576
Lipase 52 Weeks10.76 ± 27.3609.64 ± 33.715-3.66 ± 20.484
SecondaryChange From Baseline in Serum Calcitonin
Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Mean · picomole/liter
Change From Baseline in Serum Calcitonin
picomole/liter1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Week 260.01 ± 0.240-0.07 ± 0.2890.02 ± 0.256
Week 52-0.03 ± 0.279-0.08 ± 0.325-0.05 ± 0.306
SecondaryNumber of Participants With Adjudicated Cardiovascular (CV) Events

Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 weeks
Reported as:
Number · participants with adjudicated CV events
Number of Participants With Adjudicated Cardiovascular (CV) Events
participants with adjudicated CV events1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Number of Participants With Adjudicated Cardiovascular (CV) Events622
SecondaryNumber of Participants With Adjudicated Pancreatitis

The number of participants with pancreatitis confirmed by adjudication is summarized. Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 52 Weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Pancreatitis
participants1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Number of Participants With Adjudicated Pancreatitis000
SecondaryChange From Baseline in Body Weight
Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight
kilogram (kg)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Week 26-1.47 ± 0.197-0.88 ± 0.1970.97 ± 0.198
Week 52-1.08 ± 0.201-0.76 ± 0.2021.35 ± 0.201
Statistical analysis
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001 (Week 26)
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001
SecondaryChange in Body Mass Index

Body mass index is an estimate of body fat based on body weight divided by height squared.

Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Least squares mean · kilogram/square meter (kg/m2)
Change in Body Mass Index
kilogram/square meter (kg/m2)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Week 26-0.53 ± 0.071-0.32 ± 0.0710.37 ± 0.071
Week 52-0.40 ± 0.072-0.27 ± 0.0720.52 ± 0.072
Statistical analysis
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide · Mixed Models Analysis · p = <0.001
  • 1.5 mg Dulaglutide vs 0.75 mg Dulaglutide vs Insulin Glargine · Mixed Models Analysis · p = <0.001
SecondaryPercentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)

Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant was considered to have TE dulaglutide ADA if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

Time frame:
Baseline through 52 Weeks
Reported as:
Number · Percentage of participants
Percentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)
Percentage of participants1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Participants with >=1 TE Dula ADA3.94.31.6
Participants with TE Dula ADA and Neutralizing0.81.60.0
SecondaryEQ-5D Health State Score Responses

The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life. It consists of 2 parts. The first part assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 3 response categories is summarized for each of the 5 dimensions.

Time frame:
Baseline, 26 Weeks, 52 Weeks
Reported as:
Number · participants
EQ-5D Health State Score Responses
participants1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Mobility - no problem Week 26219215210
Mobility - some problem Week 2671620
Mobility - extreme problem Week 26000
Mobility - missing Week 26414
Self-care - no problem Week 26223227224
Self-care - some problem Week 26000
Self-care - extreme problem Week 26000
Self-care - missing Week 26414
Usual activities - no problems Week 26219220218
Usual activities - some problems Week 2671111
Usual activities - extreme problems Week 26000
Usual activities - missing Week 26414
Pain/Discomfort - no problems Week 26193201188
Pain/Discomfort - some problems Week 26323037
Pain/Discomfort - ambiguous000
Pain/Discomfort - missing Week 26414
Anxiety/Depression - no problems Week 26208204203
Anxiety/Depression - some problems Week 26192726
Anxiety/Depression - extreme problems Week 26001
Anxiety/Depression - missing Week 26414
Mobility - no problems Week 52218207214
Mobility - some problems Week 5281416
Mobility - extreme problems Week 52010
Mobility - missing Week 52001
Self-care - no problems Week 52224215223
Self-care - some problems Week 52277
Self-care - extreme problems Week 52000
Self-care - missing Week 52001
Usual Activities - no problems Week 52219211219
Usual Activities - some problems Week 5261011
Usual Activities - extreme problems Week 52110
Usual Activities - missing Week 52001
Pain/Discomfort - no problems Week 52191188185
Pain/Discomfort - some problems Week 52343343
Pain/Discomfort - extreme problems Week 52111
Pain/Discomfort - missing Week 52001
Anxiety/Depression - no problems Week 52205207201
Anxiety/Depression - some problems Week 52211529
Anxiety/Depression - extreme problems Week 52000
Anxiety/Depression - missing Week 52001
SecondaryChange From Baseline in EQ-5D Visual Analog Scale Score

The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. LS means of change from baseline were calculated using ANCOVA and adjusted by treatment, country, and baseline.

Time frame:
Baseline, 26 weeks, 52 weeks
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D Visual Analog Scale Score
units on a scale1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Week 261.08 ± 12.6441.67 ± 13.4561.41 ± 10.885
Week 522.65 ± 12.0292.34 ± 14.0032.55 ± 12.257

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 mg Dulaglutide—24/258 (9.3%)184/258 (71.3%)
0.75 mg Dulaglutide—15/257 (5.8%)188/257 (73.2%)
Insulin Glargine—9/253 (3.6%)157/253 (62.1%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
Event1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
Benign ovarian tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1191/1130/112
Coronary artery diseaseCardiac disorders2/2580/2570/253
PancreatitisGastrointestinal disorders2/2580/2570/253
PeriarthritisMusculoskeletal and connective tissue disorders2/2580/2570/253
Transient ischaemic attackNervous system disorders2/2581/2570/253
Angina unstableCardiac disorders0/2580/2571/253
ExtrasystolesCardiac disorders0/2580/2571/253
Sinus node dysfunctionCardiac disorders0/2580/2571/253
Vision blurredEye disorders0/2580/2571/253
BronchitisInfections and infestations1/2580/2571/253
Most frequent other events
Showing 10 of 314
Most frequent other events
Event1.5 mg Dulaglutide0.75 mg DulaglutideInsulin Glargine
HyperlipidaemiaMetabolism and nutrition disorders46/25850/25747/253
DiarrhoeaGastrointestinal disorders43/25828/2577/253
HypertensionVascular disorders20/25828/25719/253
NauseaGastrointestinal disorders27/25814/2572/253
Lipase increasedInvestigations27/25818/2572/253
NasopharyngitisInfections and infestations18/25817/25722/253
Decreased appetiteMetabolism and nutrition disorders19/25814/2570/253
Abdominal distensionGastrointestinal disorders18/25813/2570/253
VomitingGastrointestinal disorders16/2586/2572/253
Urinary tract infectionInfections and infestations13/25814/25711/253

Baseline characteristics

Baseline characteristics are reported for the modified intent-to-treat (mITT) population, who are all randomized participants with a baseline glycosylated hemoglobin (HbA1c) measurement, at least 1 post-baseline HbA1c measurement, and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin GlargineTotal
Mean55.03 ± 9.57254.54 ± 10.00655.44 ± 9.19755.00 ± 9.593
Sex: Female, Male
Sex: Female, Male(Participants)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin GlargineTotal
Female118109111338
Male135143139417
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin GlargineTotal
American Indian or Alaska Native14141341
Asian213209209631
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White26292883
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)1.5 mg Dulaglutide0.75 mg DulaglutideInsulin GlargineTotal
China200196195591
Korea, Republic of13131440
Mexico22242470
Russian Federation18191754
08

Study locations

30 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100730, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410011, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chengdu, 610041, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chongqing, 400030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dalian, 116011, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guang Zhou, 510120, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guiyang, 550004, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310009, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Harbin, 150001, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hefei, 230022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanchang, 330006, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanjing, 210006, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanning, 530021, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200080, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shenyang, 110004, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shijiazhuang, 050051, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wu Han, 430022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Xi'An, 710032, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yangzhou, 225001, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zhenjiang, 212000, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucheon,, 420-717, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyunggi-Do, 425-020, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 137-701, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wonju-Si, 220-701, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chihuahua, 31238, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64460, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chelyabinsk, 454047, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 127018, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Petersburg, 192012, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sankt-Petersburg, 190000, Russian Federation
09

References and documents

Publications

  • Cai TT, Li HQ, Jiang LL, Wang HY, Luo MH, Su XF, Ma JH. Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study. Biomed Res Int. 2021 Sep 17;2021:3361309. doi: 10.1155/2021/3361309. eCollection 2021. PubMed 34580638 ↗
  • Zhou Y, Zhu J, Wu H, Deng Y, Ji Q. Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors. Diabetes Ther. 2021 Oct;12(10):2677-2690. doi: 10.1007/s13300-021-01139-2. Epub 2021 Aug 28. PubMed 34453682 ↗
  • Ma J, Zhang B, Hou J, Peng Y. Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors. Diabetes Ther. 2021 Jan;12(1):211-222. doi: 10.1007/s13300-020-00955-2. Epub 2020 Nov 8. PubMed 33161492 ↗
  • Kuang J, Zhu J, Liu S, Li Q. Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies. Diabetes Ther. 2020 Oct;11(10):2329-2339. doi: 10.1007/s13300-020-00910-1. Epub 2020 Aug 28. PubMed 32857293 ↗
  • Guo L, Zhang B, Hou J, Zhou Z. Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials. Diabetes Ther. 2020 Aug;11(8):1821-1833. doi: 10.1007/s13300-020-00869-z. Epub 2020 Jul 4. PubMed 32621083 ↗
  • Yu M, Yuan GY, Zhang B, Wu HY, Lv XF. Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis. Diabetes Ther. 2020 May;11(5):1147-1159. doi: 10.1007/s13300-020-00804-2. Epub 2020 Apr 10. PubMed 32277401 ↗
  • Wang J, Li HQ, Xu XH, Kong XC, Sun R, Jing T, Ye L, Su XF, Ma JH. The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus. Biomed Res Int. 2019 Dec 24;2019:2682657. doi: 10.1155/2019/2682657. eCollection 2019. PubMed 31950036 ↗
  • Li Y, Li L, De Peng Y, Song GY, Ye SD, Du LY, Hou JN, Ji QH. Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2). Diabetes Ther. 2019 Aug;10(4):1435-1452. doi: 10.1007/s13300-019-0646-y. Epub 2019 Jun 21. PubMed 31228090 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Aug 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 11 months after primary completion. A results delay was requested in Sep 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2012
First posted
Jul 24, 2012
Start
Jul 2012
Primary completionActual
Aug 2014
CompletionActual
Dec 2014
Results delay requested
Sep 29, 2014
Results first posted
Jul 24, 2015
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01648582
Responsible party
Sponsor
First posted
Jul 24, 2012
Start date
Jul 2012
Primary completion
Aug 2014
Completion
Dec 2014
Results posted
Jul 24, 2015
Last update
Sep 18, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion